words lines 0 60 0 20 top 50% bottom top 1 0 0 .22 back 1 0 .001 1 .1 1.5 none top bottom center center true 1 none top top center top true 0 200 .001 none
top bottom top center true 1 none top bottom bottom bottom true 1 none

Press Releases

Advancing Healthcare Innovation: Juniper Biologics Recognized as the Best Novel Therapy R&D and Commercialization Company 2024 by APAC Insider

By Juniper Biologics / March 25, 2024 / Comments Off on Advancing Healthcare Innovation: Juniper Biologics Recognized as the Best Novel Therapy R&D and Commercialization Company 2024 by APAC Insider

SINGAPORE, 25 MARCH 2024 – Juniper Biologics (“Juniper”), Singapore-based science-led pharmaceutical company focused on researching, developing, and commercializing novel therapies, celebrates another milestone as it received the award for Best Novel Therapy R&D and Commercialization Company at the APAC Insider Singapore Business Awards 2024. The APAC Insider Singapore Business Awards serves to spotlight companies and … Read more

Read More

Juniper Biologics Clinches Prestigious Molecular Science & Technology Acquisition of the Year Award at the Acquisition International M&A Awards 2023

By Juniper Biologics / January 10, 2024 / Comments Off on Juniper Biologics Clinches Prestigious Molecular Science & Technology Acquisition of the Year Award at the Acquisition International M&A Awards 2023

2024-01-08 09:00 SINGAPORE, Jan. 8, 2024 /PRNewswire/ — Juniper Biologics (“Juniper“), a global science-led pharmaceutical company headquartered in Singapore, proudly announces its latest achievement, winning the award for Molecular Science & Technology Acquisition of the Year at Acquisition International’s M&A Awards 2023. This recognition highlights Juniper’s unwavering commitment to advancing treatments in oncology-supportive care and its … Read more

Read More

Juniper Therapeutics Acquires Exclusive Rights for SAR Registration for Anti-Viral COVID-19 Drug from Ping An-Shionogi Hong Kong for Singapore

By Juniper Biologics / December 22, 2023 / Comments Off on Juniper Therapeutics Acquires Exclusive Rights for SAR Registration for Anti-Viral COVID-19 Drug from Ping An-Shionogi Hong Kong for Singapore

https://www.prnewswire.co.uk/news-releases/juniper-therapeutics-acquires-exclusive-rights-for-sar-registration-for-anti-viral-covid-19-drug-from-ping-an-shionogi-hong-kong-for-singapore-302021003.html?tc=eml_cleartime

Read More

Singapore-based Juniper Biologics Awarded the Most Innovative Oncology Pharmaceutical Company 2023 by GHP Healthcare and Pharmaceutical Awards

By Juniper Biologics / October 23, 2023 / Comments Off on Singapore-based Juniper Biologics Awarded the Most Innovative Oncology Pharmaceutical Company 2023 by GHP Healthcare and Pharmaceutical Awards

SINGAPORE, 23 OCTOBER 2023 – Juniper Biologics, a global science-led pharmaceutical company headquartered in Singapore, has been honored with the prestigious title of the “Most Innovative Oncology Pharmaceutical Company 2023” by the Global Health & Pharma (GHP) Healthcare and Pharmaceutical Awards. This recognition underscores Juniper Biologics’ commitment to advancing healthcare by delivering groundbreaking therapies in … Read more

Read More

JUNIPER BIOLOGICS PARTNERS WITH CARIS LIFE SCIENCES® FOR MOLECULAR PROFILING DISTRIBUTION IN SOUTH EAST ASIA

By Juniper Biologics / January 12, 2023 / Comments Off on JUNIPER BIOLOGICS PARTNERS WITH CARIS LIFE SCIENCES® FOR MOLECULAR PROFILING DISTRIBUTION IN SOUTH EAST ASIA

SINGAPORE, JANUARY 12, 2023: Singapore-headquartered Juniper Biologics Pte Ltd, a science-led healthcare company focused on commercialising novel therapies, has been granted distribution rights for Caris Life Sciences® (Caris)’ molecular profiling services in South East Asia. Caris is the leading molecular science and technology company actively developing and delivering innovative solutions to revolutionize healthcare. The company’s … Read more

Read More

Helsinn Healthcare SA signs exclusive license agreement with Juniper Biologics Pte. Ltd. for LEDAGA® (chlormethine) in Australia, Asia and the Middle East*

By Juniper Biologics / September 1, 2022 / Comments Off on Helsinn Healthcare SA signs exclusive license agreement with Juniper Biologics Pte. Ltd. for LEDAGA® (chlormethine) in Australia, Asia and the Middle East*

Lugano, Switzerland, September 1, 2022 – Helsinn Group (“Helsinn”), a fully integrated, global biopharma company with a diversified pipeline of innovative oncology assets and strong track-record of commercial execution, and Juniper Biologics Pte Ltd, a science-led healthcare company focused on researching, developing and commercializing novel therapies, announced today the signing of an exclusive distribution license and … Read more

Read More

Juniper Biologics signs exclusive license agreement with Helsinn for infigratinib (INN) for the emerging markets*

By Juniper Biologics / May 4, 2022 / Comments Off on Juniper Biologics signs exclusive license agreement with Helsinn for infigratinib (INN) for the emerging markets*

Juniper Biologics Pte Ltd announced today the signing of an exclusive license agreement to develop and commercialise infigratinib (INN) in Australia, New Zealand, Southeast Asia and certain markets in the Middle East and Africa.

Read More

Juniper Biologics Acquires Cell-Mediated Gene Therapy TG-C LD For Treatment of Knee Osteoarthritis

By Juniper Biologics / April 13, 2022 / Comments Off on Juniper Biologics Acquires Cell-Mediated Gene Therapy TG-C LD For Treatment of Knee Osteoarthritis

$600 million USD acquisition will see Juniper Biologics offer the world’s first cell-mediated gene therapy to an estimated 300 million patients in Asia Pacific, Middle East and Africa.

Read More

Juniper Biologics In-Licenses Helsinn’s Oncology Portfolio For Aloxi®, Onicit®, Paloxi®, Akynzeo® and Anamorelin (INN)

By Juniper Biologics / December 22, 2021 / Comments Off on Juniper Biologics In-Licenses Helsinn’s Oncology Portfolio For Aloxi®, Onicit®, Paloxi®, Akynzeo® and Anamorelin (INN)

Helsinn Healthcare SA announced the signing of exclusive distribution, license and supply agreements for Aloxi®, Onicit®, Paloxi®, Akynzeo® (IV and oral formulations) and anamorelin (INN).

Read More

Juniper Biologics Announces the Appointment of Raman Singh as Chief Executive

By Juniper Biologics / April 22, 2021 / Comments Off on Juniper Biologics Announces the Appointment of Raman Singh as Chief Executive

Juniper Biologics has announced the appointment of celebrated pharmaceutical executive Raman Singh to the role of Chief Executive.

Read More